A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma
Keyword(s):
Phase I
◽
2014 ◽
Vol 73
(3)
◽
pp. 539-549
◽
2014 ◽
Vol 20
(24)
◽
pp. 6284-6294
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 2531-2531
◽